
India approves 30% margin cap for cancer drugs
Published 9 Oct 2026
14 Nov 2026
India is reducing the cost of many cancer medicines by limiting distributor and pharmacy trade margins on 137 non-scheduled anti-cancer drugs to 30%, following evidence that high markups inflated patient prices. The policy, implemented through revised maximum retail prices, covers patented and non-patented medicines and has produced reductions ranging from modest cuts to more than 96% across reported formulations and brands. It expands on an earlier pricing intervention and is expected to generate substantial annual savings, while not placing every medicine under conventional legal price control. The central challenge is ensuring that manufacturers, distributors, pharmacies and states apply the new prices consistently, so projected savings reach patients rather than being eroded by supply gaps, uneven compliance or overcharging.

Published 9 Oct 2026

Published 9 Nov 2026

Published 14 Nov 2026